Platinib’s latest selling price and medical insurance reimbursement details in 2024

Platinib, as a targeted therapy drug targeting specific genetic mutations, has shown remarkable efficacy in the field of cancer treatment in recent years. However, its high price has always been unaffordable for patients. In my country, the original drug Platinib is already on the market, but the price of a box is as high as tens of thousands of yuan, and it is not yet included in medical insurance, so patients need to pay for it at their own expense. This undoubtedly puts huge financial pressure on patients and their families.

In order to reduce the financial burden on patients, Lucius Pharmaceuticals Laos has launched a generic version of Platinib. The price of this version is relatively affordable, with each box selling for about more than 4,000 yuan, which is only a fraction of the price of the original drug, which greatly reduces the treatment cost for patients. At the same time, the version of Platinib produced by Lucius Pharmaceuticals in Laos has been officially approved by the Ministry of Health of Laos. It is a regular drug, its quality is guaranteed, and patients can use it with confidence.

Although the Lao version of platinib provides patients with a more economical treatment option, there are still certain risks in purchasing the drug overseas. Patients must choose guaranteed formal channels when purchasing to avoid buying fake or inferior drugs. It is recommended that patients choose professional overseas medical institutions for consultation, and carefully check the packaging, labels and manufacturer information of the drugs to ensure that they are purchasing genuine products.

As for medical insurance reimbursement, my country has not yet included Platinib in the medical insurance catalog. This means that if patients choose to purchase original drugs domestically, they need to pay the full amount out of their own pocket. However, with the continuous improvement of medical insurance policies and the gradual expansion of the reimbursement scope of anti-cancer drugs, we have reason to believe that highly effective anti-cancer drugs such as platinib are expected to be included in medical insurance in the future to provide patients with more financial support.

In general, platinib, as a targeted treatment drug targeting specific genetic mutations, has significant efficacy but is expensive. The emergence of the Lao version of platinib provides patients with a more economical treatment option. However, during the purchase process, patients still need to choose the channel carefully to ensure the safety and effectiveness of the medication. At the same time, we hope that the government will include platinib in medical insurance as soon as possible to reduce the financial burden on patients.